Effects Of Chitosan-coated Levodopa Liposomes On Levodopa-induced Dyskinesia In Rats

Objective To study the effect to behavioral character and changes of phosphorylated Mr32000dopamine-and cyclic adenosine monophosphate-regulated phosphoprotein (DARPP-32) and FosB/AFosB in striatum of rat model of levodopa-induced dyskinesia (LID) by chitosan-coated levodopa liposomes.Methods Unilateral6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson disease (PD) was treated separatedly with chitosan-coated levodopa liposomes/carbidopa and levodopa/carbidopa once daily for4weeks and the behavior was observed on the1st,4th,8th,12th,16th,20th,24th and27th day. Then the animals were sacrificed, Phospho-Thr34DARPP-32level in striatum were measured by western blotting technique, and FosB/△FosB level in striatum were measured by immunohistochemical method.Results Scores of abnormal involuntary movement(AIM) decreased significantly in liposome group (P<0.05) compared with levodopa group (P<0.05). Levels of phospho-Thr34DARPP-32and FosB/△FosB in striatum increased significantly in levodopa group lesion side(P<0.05) and liposome group lesion side(P<0.05) compared with control group. However in liposome group lesion side, the expression of phospho-Thr34DARPP-32and FosB/△FosB in striatum decreased compared with levodopa group lesion side, and the differences between them were significant (P<0.05).Conclusion Chitosan-coated levodopa liposomes may be useful in the prevention and treatment of AIMs.